As technologies evolve and healthcare innovation accelerates, the traditional boundaries separating medtech, big tech, and big pharma are increasingly blurry — but the cultural and strategic gaps between them remain. At LSI USA ’25, panelists Juan-Pablo Mas (Action Potential Venture Capital), Nishant Doctor (Surf Therapeutics), and Jordi Parramon (Nexus NeuroTech Ventures) joined moderator Katie Elias to examine how medtech can better align with big tech and big pharma to drive innovation forward. The conversation centered on key differences in development strategy, investor expectations, and business timelines — critical challenges that arise when building partnerships or raising capital across sectors. As medtech companies seek broader platforms and more ambitious outcomes, understanding and navigating these differences becomes essential for effective cross-sector collaboration and long-term success. Understanding the Evidence Gap A major area of divergence bet...
Comments
Post a Comment